About us

We are Odix, a start-up company founded in October 2020. Our mission is to stimulate the evolution of orthopedic rehabilitation with innovative approaches to improve the patient's quality of life.

Our first project, LumbaCure®, focuses on Low Back Pain, one of the leading causes of disability worldwide affecting 14% of the population globally. We aim to become an international reference in orthopedic rehabilitation equipment.

LumbaCure® is an innovative activating device which delivers a specific mobilization of the low back structure. It provides a new therapeutic approach that leads to a faster and lasting reduction of both back pain and disability. It enhances the rehabilitation process in combination with physical exercises.

The device’s market launch is planned for early 2027. As of now, we are looking for financial and business partners to make this endeavor a success.


Low Back Pain

Project pipeline

  • Feasibility
  • Engineering Prototype
  • Pilot Clinical Trial
  • Design & Engineering Pivotal Clinical Studies
  • Registration
  • Feasibility
  • Engineering Prototype
  • Pilot Clinical Trial
  • Design & Engineering

    Pivotal Clinical Studies

  • Registration
  • LumbaCure®

The Pathology

Based on the "Global burden disease study”, Low Back Pain was classified as the most harmful, non-fatal disease and the leading cause of disability worldwide with high socio-economic impact. Back pain results in subjectively impaired health, reduced performance in everyday life and work, and even withdrawal from social life or complete loss of quality of life. Back pain leads to absenteeism from work and reduced productivity. The condition affects at any time 30 mio of people in US and 60 mio of people in Europe (prevalence > 7.5%). The expectations for the next 30 years are a gradual worsening of those figures by a factor of 1.5. Patients with back pain are therefore a major challenge for the healthcare system. Furthermore, the restriction of participation and quality of life associated with the disease calls for innovative new therapeutic approaches that lead to a faster and lasting reduction of back pain.

Mattiuzzi et al. 2020 – Current epidemiology of low back pain – Journal of Hospital Management and Health Policy Dutmer et al. 2019 – Personal and societal impact of low back pain

Leading cause
of disability

+ 550 Mio cases

1 to 2 % of
Gross Domestic


LumbaCure® is a mobile seating platform driven by a proprietary movement algorithm to deliver an active and specific low back mobilization. This robotic device is combined with a native patient interface focusing on patient motivation, cognitive therapy and individualized care. It provides a new therapeutic approach that leads to a faster and lasting reduction of both back pain and disability. This project is financially supported by SPW Wallonia DGO6.


Follow us on Linkedin and Euroquity to see our upcoming events and capital increase

To achieve our mission, we are looking for financial partners.

LumbaCure®'s market launch is planned for early 2027. A total capital increase of €7 million, in different milestones, is needed to reach the end of the 1st year of commercialization. The first milestone is the completion by mid-2026 of pivotal clinical study and of the final product’s design and engineering, ready for production and regulatory procedures. To achieve this next step, we require a total of €3.5 million, including grants and capital brought by current investors. We are looking for an immediate €1.8 million.


Odix is open to partnering in other innovative projects, related to our field of expertise. Different types of partnerships are possible: co-development, joint ventures for projects at different levels of maturity, or un-exploited patents.


We are looking for partnerships for the worldwide distribution/commercialization of our LumbaCure® device.

Want to present us your
project or new idea ?


Gordenne Valerie
founder & CEO

Industrial pharmacist with more than 20 years of experience in pharma industry in drug development, regulatory and manufacturing, former CSO of Mithra Pharmaceuticals


Frankenne Francis
founder & CSO

Doctor in Biochemistry, at the origin of the idea of LumbaCure® project, creation of Mithra's research Department and research portfolio Management (2000 - 2012), former CEO of Belma s.a. and Themise s.a.


Delcorps Xavier
founder & CCO

Master in Sport Sciences & Kinesiology with 25 years' experience in Medical Devices, International Business Development, former CCO Spentys s.a.


Deflandre Sophie
project leader

Graduated in Biomedical Engineering from ULiege in 2021 and trained in entrepreneurship at HEC


Financial partners


Do you want to participate in the future of orthopedic rehabilitation?

Contact Us